Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Triple COVID-19 Antibody Testing Device Indicates Prior SARS-CoV-2 Infection and If Your Vaccine Worked

By LabMedica International staff writers
Posted on 19 Aug 2021
A new seven-minute COVID-19 antibody testing device can tell you if you have had COVID-19 and if your vaccine worked.

Mantracourt Electronics Limited (Devon, UK) helped engineer the new COVID-19 triple antibody testing device which was designed by Attomarker Ltd. More...
(Exeter, UK) and will tell people whether they have immunity against coronavirus and whether that immunity comes from developing antibodies after infection or the vaccine.

The Triple Antibody Test measures three types of antibodies: IgM – the first-responding antibody raised early in the infection; IgG – the long-lasting antibody, persisting in the blood for possibly six months; and IgA – the antibody released on surfaces of the nose and lungs as the first line of defense. These antibodies attack three different parts of the coronavirus: Nucleocapsid - the protein containing the RNA material inside the virus; Spike Protein – the protein that attaches to the surfaces of our cells when the virus invades; and RBD Protein – the part of the spike protein that docks to our cells leading to neutralizing antibodies.

The Triple Antibody Test tells you whether you have natural antibodies because you have had the infection before and which protect you against infection, or if you have vaccine antibodies to protect you against infection. The results appear in real-time and will be an evolving graph which at the end of the test shows the three antibody levels N, S, and RBD along with CRP. If the test reveals that you have antibodies above pre-pandemic levels, then you have some protection and if the results show that you have antibodies below pre-pandemic levels, then you may not have protection against the virus. The results can be downloaded straight to the Biomark App.

“We started off by building the device for Attomarker, but it quickly became apparent that there were other areas where we could assist to deliver the project such as machine validation testing,” explained Robert Badcock, managing director at Mantracourt. “We undertook pre-compliance testing and discovered the electronics and communication systems in the device could be improved. We designed a new power distribution module, new USB components and a USB hub, as well as replacing several of the specified cables in the unit. Overall, we managed to improve the kit while reducing around 60 per cent of the cost and also reduced noise, which is important from an EMC point of view.”

Related Links:
Mantracourt Electronics Limited
Attomarker Ltd.



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.